• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺癌的更新分期系统。

Updated staging system for lung cancer.

作者信息

Goldstraw Peter

机构信息

Academic Department of Thoracic Surgery, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.

出版信息

Surg Oncol Clin N Am. 2011 Oct;20(4):655-66. doi: 10.1016/j.soc.2011.07.005.

DOI:10.1016/j.soc.2011.07.005
PMID:21986263
Abstract

The seventh edition of TNM for Lung Cancer came into effect on the first of January 2011. Containing more than 100,000 cases of lung cancer treated by all modalities of care and from around the world, this is the largest database ever accumulated for this purpose. This edition allows detailed analysis and intensive validation such that the resultant classification aligns stage with prognosis more closely than ever before. There have been changes to certain tumor and metastasis descriptors and the resultant stage groupings. This article describes these changes, provides more in-depth discussion of the changes, and provides much additional information.

摘要

《肺癌TNM分期系统》第七版于2011年1月1日生效。该数据库包含全球各地超过100,000例接受各种治疗方式的肺癌病例,是有史以来为该目的积累的最大数据库。此版本允许进行详细分析和深入验证,从而使最终的分类比以往任何时候都更紧密地将分期与预后联系起来。某些肿瘤和转移描述符以及由此产生的分期分组发生了变化。本文描述了这些变化,对这些变化进行了更深入的讨论,并提供了更多附加信息。

相似文献

1
Updated staging system for lung cancer.肺癌的更新分期系统。
Surg Oncol Clin N Am. 2011 Oct;20(4):655-66. doi: 10.1016/j.soc.2011.07.005.
2
Updated lung cancer staging system.更新的肺癌分期系统。
Future Oncol. 2009 Dec;5(10):1545-53. doi: 10.2217/fon.09.131.
3
New TNM classification for non-small-cell lung cancer.非小细胞肺癌的新TNM分类
Expert Rev Anticancer Ther. 2009 Apr;9(4):413-23. doi: 10.1586/era.09.11.
4
Treatment implications of the new lung cancer staging system.新肺癌分期系统的治疗意义。
Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS7-eS10. doi: 10.3949/ccjm.79.s2.02.
5
TNM-classification for lung cancer: from the 7th to the 8th edition.肺癌的TNM分期:从第7版到第8版。
Acta Chir Belg. 2011 Nov-Dec;111(6):389-92.
6
The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours.国际肺癌研究协会肺癌分期项目:对即将出版的(第七版)恶性肿瘤TNM分类中T、N和M描述符修订提案及相应分期分组的验证。
J Thorac Oncol. 2007 Aug;2(8):694-705. doi: 10.1097/JTO.0b013e31812d05d5.
7
New staging system: how does it affect our practice?新的分期系统:它如何影响我们的实践?
J Clin Oncol. 2013 Mar 10;31(8):984-91. doi: 10.1200/JCO.2012.42.7922. Epub 2013 Feb 11.
8
The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer.第七版肺癌肿瘤、淋巴结、转移分期系统背后的科学。
Respirology. 2012 Feb;17(2):247-60. doi: 10.1111/j.1440-1843.2011.02083.x.
9
A radiologic review of the new TNM classification for lung cancer.肺癌新 TNM 分类的放射学评价。
AJR Am J Roentgenol. 2010 Mar;194(3):562-73. doi: 10.2214/AJR.09.3354.
10
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.IASLC 肺癌分期项目:对即将发布的(第八版)肺癌 TNM 分类中 TNM 分期分组的修订建议。
J Thorac Oncol. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.

引用本文的文献

1
ZNF131-BACH1 transcriptionally accelerates RAD51-dependent homologous recombination repair and therapy-resistance of non-small-lung cancer cells by preventing their degradation from CUL3.锌指蛋白131-巴赫1通过阻止非小细胞肺癌细胞因CUL3而降解,转录加速其依赖RAD51的同源重组修复及治疗抗性。
Theranostics. 2024 Oct 28;14(18):7241-7264. doi: 10.7150/thno.97593. eCollection 2024.
2
Up-Regulation of p53/miR-628-3p Pathway, a Novel Mechanism of Shikonin on Inhibiting Proliferation and Inducing Apoptosis of A549 and PC-9 Non-Small Cell Lung Cancer Cell Lines.紫草素抑制A549和PC-9非小细胞肺癌细胞系增殖及诱导凋亡的新机制:p53/miR-628-3p通路的上调
Front Pharmacol. 2021 Nov 16;12:766165. doi: 10.3389/fphar.2021.766165. eCollection 2021.
3
MiR-133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-β/Smad3 signaling pathway.miR-133a 通过调节 LASP1 和 TGF-β/Smad3 信号通路在肺癌进展中发挥肿瘤抑制作用。
Thorac Cancer. 2020 Dec;11(12):3473-3481. doi: 10.1111/1759-7714.13678. Epub 2020 Oct 19.
4
ANKHD1 promotes proliferation and invasion of non‑small‑cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway.ANKHD1 通过调节 YAP 癌蛋白表达和失活 Hippo 通路促进非小细胞肺癌细胞的增殖和侵袭。
Int J Oncol. 2020 May;56(5):1175-1185. doi: 10.3892/ijo.2020.4994. Epub 2020 Feb 19.
5
New insights into small-cell lung cancer development and therapy.小细胞肺癌发生发展与治疗的新认识。
Cell Biol Int. 2020 Aug;44(8):1564-1576. doi: 10.1002/cbin.11359. Epub 2020 Apr 18.
6
Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis.角蛋白17(KRT17)的过表达促进非小细胞肺癌的增殖和侵袭,并提示预后不良。
Cancer Manag Res. 2019 Aug 7;11:7485-7497. doi: 10.2147/CMAR.S218926. eCollection 2019.
7
SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients.富含 SET 结构域蛋白 5(SETD5)增强肿瘤细胞侵袭能力,并与非小细胞肺癌患者的不良预后相关。
BMC Cancer. 2019 Jul 25;19(1):736. doi: 10.1186/s12885-019-5944-2.
8
FRMPD1 activates the Hippo pathway via interaction with WWC3 to suppress the proliferation and invasiveness of lung cancer cells.FRMPD1通过与WWC3相互作用激活Hippo信号通路,以抑制肺癌细胞的增殖和侵袭。
Cancer Manag Res. 2019 Apr 18;11:3395-3410. doi: 10.2147/CMAR.S194512. eCollection 2019.
9
LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.长链非编码RNA MALAT1通过直接作用于miR-197-3p/p120连环蛋白轴降低非小细胞肺癌细胞的化疗敏感性。
Mol Cells. 2019 Mar 31;42(3):270-283. doi: 10.14348/molcells.2019.2364. Epub 2019 Feb 19.
10
FAM98A promotes proliferation of non-small cell lung cancer cells via the P38-ATF2 signaling pathway.FAM98A通过P38-ATF2信号通路促进非小细胞肺癌细胞的增殖。
Cancer Manag Res. 2018 Jul 27;10:2269-2278. doi: 10.2147/CMAR.S163323. eCollection 2018.